![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Health Canada Begins Rolling Review of Medicago’s COVID-19 Vaccine
Health Canada Begins Rolling Review of Medicago’s COVID-19 Vaccine
![HealthCanada_Logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images2/HealthCanada_Logo.gif?t=1576125138&width=430)
Health Canada has launched a rolling review of Medicago’s two-dose COVID-19 vaccine candidate that is currently being evaluated in a phase 3 trial.
The plant-based vaccine contains a recombinant spike glycoprotein that mimics the SARS-CoV-2 virus in order to induce a protective immune response to the virus. It also features an adjuvant supplied by GlaxoSmithKline.
The late-stage study aims to enroll up to 30,000 individuals across 10 countries. The trial’s completion date is set for the end of April 2022, according to ClinicalTrials.gov.
Upcoming Events
-
18Jul
-
21Oct